Prostate News Archive
27-Jan-2007
Ciphergen Announces Issuance of European Patent Covering a Method for Aiding Prostate Cancer Diagnosis (PR Newswire via Yahoo! Finance)
Ciphergen Biosystems, Inc. today announced that the European Patient Office has issued EU Patent No. 1 224 466, entitled "prostate Cancer Marker Proteins," for aiding in prostate cancer diagnosis. Spectrum Pharmaceuticals Initiates Phase 2b Trial for Ozarelix in Patients with Benign Prostate Hypertrophy (PR Newswire via Yahoo! Finance)
Spectrum Pharmaceuticals, Inc. announced today that the first patient has been dosed in the company's Phase 2b study of ozarelix in the U.S. in patients with benign prostate hypertrophy . No Link Between Viral Findings In The Prostate And Subsequent Cancer Development (Medical News Today)
UroToday.com- Recently, mutations in genes associated with immune defense and a link to the development of prostate cancer (CaP) has been proposed by several scientific studies. In addition, epidemiologic reports suggest that men with prior history of sexually transmitted infections have an increased relative risk for development of CaP. Based upon these reports Dr. [click link for full article]
Back to Prostate News Archive
